134 related articles for article (PubMed ID: 12112387)
1. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
2. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
Wang L; Roy SK; Eastmond DA
Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
4. Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe.
Attia SM; Kliesch U; Schriever-Schwemmer G; Badary OA; Hamada FM; Adler ID
Environ Mol Mutagen; 2003; 41(2):99-103. PubMed ID: 12605378
[TBL] [Abstract][Full Text] [Related]
5. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
6. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication.
Pastor N; Domínguez I; Orta ML; Campanella C; Mateos S; Cortés F
Mutat Res; 2012; 738-739():45-51. PubMed ID: 22921906
[TBL] [Abstract][Full Text] [Related]
7. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
Khélifa T; Beck WT
Mol Pharmacol; 1999 Mar; 55(3):548-56. PubMed ID: 10051540
[TBL] [Abstract][Full Text] [Related]
8. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
Olaharski AJ; Mondrala ST; Eastmond DA
Mutat Res; 2005 Apr; 582(1-2):79-86. PubMed ID: 15781213
[TBL] [Abstract][Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
Anderson H; Roberge M
Cell Growth Differ; 1996 Jan; 7(1):83-90. PubMed ID: 8788036
[TBL] [Abstract][Full Text] [Related]
12. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
13. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Hirota H; Gosky D; Berger NA; Chatterjee S
Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
[TBL] [Abstract][Full Text] [Related]
14. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
15. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
16. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
17. Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy.
Kallio M; Lähdetie J
Environ Mol Mutagen; 1997; 29(1):16-27. PubMed ID: 9020303
[TBL] [Abstract][Full Text] [Related]
18. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
Constantinou AI; Husband A
Anticancer Res; 2002; 22(5):2581-5. PubMed ID: 12529967
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe K; Ikegami Y; Ishida R; Andoh T
Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
[TBL] [Abstract][Full Text] [Related]
20. Chromosome analysis of mouse one-cell androgenones derived from a sperm nucleus exposed to topoisomerase II inhibitors at pre- and post-fertilization stages.
Tateno H; Kamiguchi Y
Mutat Res; 2004 Nov; 556(1-2):117-26. PubMed ID: 15491639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]